A genome-wide association study of inflammatory biomarker changes in response to fenofibrate treatment in the Genetics of Lipid Lowering Drug and Diet Network

Pharmacogenetics and genomics, 02/24/2012

Authors have identified several novel biologically relevant loci associated with systemic inflammation before and after fenofibrate treatment.

Methods

  • Biomarkers of inflammation were measured in participants of the Genetics of Lipid Lowering Drugs and Diet Network (n=1092) before and after a 3–week daily treatment with 160 mg of fenofibrate.
  • Two inflammatory patterns [high–sensitivity C–reactive protein–interleukin–6 and monocyte chemoattractant protein–1–tumor necrosis factor (MCP1–TNF–α)] were derived using principal component analysis.
  • Associations between single nucleotide polymorphisms on the Affymetrix 6.0 chip and phenotypes were assessed using mixed linear models, adjusted for age, sex, study center, and ancestry as fixed effects and pedigree as a random effect.

Results

  • Before fenofibrate treatment, the strongest evidence for association was observed for polymorphisms near or within the IL2RA gene with the high–sensitivity C–reactive protein–interleukin–6 (IL6) pattern (rs7911500, P=5×10–9 and rs12722605, P=5×10–8).
  • Associations of the MCP1–TNF–α pattern with loci in several biologically plausible genes [CYP4F8 (rs3764563), APBB1IP (rs1775246), COL13A1 (rs2683572), and COMMD10 (rs1396485)] approached genome–wide significance (P=3×10–7, 5×10–7, 6×10–7, and 7×10–7, respectively) before fenofibrate treatment. After fenofibrate treatment, the rs12722605 locus in IL2RA was also associated with the MCP1–TNF– α pattern (P=3×10–7).
  • The analyses of individual biomarker response to fenofibrate did not yield genome–wide significant results, but the rs6517147 locus near the immunologically relevant IFNAR2 gene was suggestively associated with IL6 (P=7×10–7).

Print Article Summary Cat 2 CME Report